Lexicon Pharmaceuticals (LXRX) Share-based Compensation (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Share-based Compensation of $3.1 million for Q1 2026, up 1.15% year-over-year from $3.0 million in Q1 2025, and up 7058.14% quarter-over-quarter from $43000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Share-based Compensation (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Share-based Compensation for 17 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 1.15% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $6.6 million (down 27.78% YoY), while the FY2025 annual figure was $3.2 million, down 75.98% from the prior year.
- Share-based Compensation grew to $3.1 million in Q1 2026 per LXRX's latest filing, from $43000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.3 million in Q1 2024 and bottomed at -$10.3 million in Q4 2023.
- Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $2.6 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 139.14% — and 2023, when it tumbled 415.3%.
- Lexicon Pharmaceuticals' Share-based Compensation stood at $3.3 million in 2022, then sank by 415.3% to -$10.3 million in 2023, then soared by 114.92% to $1.5 million in 2024, then sank by 97.2% to $43000.0 in 2025, then jumped by 7058.14% to $3.1 million in 2026.
- Business Quant data shows LXRX's Share-based Compensation at $3.1 million in Q1 2026, $43000.0 in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Mn |
| Jun 30, 2026 | 1.95 Mn |
| Mar 31, 2026 | 3.08 Mn |
| Mar 31, 2026 | 3.08 Mn |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 3.04 Mn |
| Mar 31, 2025 | 3.04 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | 4.30 Mn |
| Mar 31, 2024 | 4.30 Mn |